U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Not Yet Assigned 10/8/4,194 **Application Number** INFORMATION DISCLOSURE Filing Date **Even Date Herewith** STATEMENT BY APPLICANT Johan FROSTEGARD First Named Inventor Group Art Unit · (use as many sheets as necessary) **Examiner Name** . Cook Sheet of 2 Attorney Docket Number FROSTEGARD=1C

		•	U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LYC	AA	US-5,731,208	03-24-1998	HEINECKE	
		US-			·
		US-			

		FOREIC	GN PATENT DO	CUMENTS		
		Foreign Patent Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	I of Oldert Description	Where Relevant Passages or Relevant Figures Appear	T ⁶
ļ	ļ					
 -	 			<u> </u>		
	ļ					
 _						
						-
				-		\vdash

Examiner Signature Signature	Date Considered	12/7/05	•

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.18 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Complete if Known Substitute for form 1449A/PTO Not Yet Assigned Application Number **INFORMATION DISCLOSURE** Filing Date **Even Date Herewith** STATEMENT BY APPLICANT Johan FROSTEGARD First Named Inventor **Group Art Unit** (use as many sheets as necessary) **Examiner Name** L. COOF Sheet of 2 Attorney Docket Number FROSTEGARD=1C

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
LYC	АВ	BALDO et al, "A specific, sensitive, and high capacity immunoassay for PAF". 1991). 26(12):1136-1139.	
	AC	BARQUINERO, Jordi, et al "Antibodies Against Platelet-Activating Factor In Patients With Antiphospholipid Antibodies". Lupus, Vol. 3 (1994), pp. 55-58.	
	AD	FROSTEGARD et al, "Association of Serum Antibodies to Heat-Shock Protein 65 With Borderline Hypertension", HYPERTENSION, 29(1), pp. 40-44, 1997.	
	AE	FROSTEGARD et al, "Platelet-Activating Factor and Oxidized LDL Induce Immune Activation by a Common Mechanism", ARTERIOSCLEROSIS, 17(5), pp 963-968, 1997.	
	AF	HARRIS et al, "Evaluation of the Anti-Cardiolipin Antibody Test: Report of an International Workshop held 4 April 1986:, Clin. Exp Immunol, 1987 Apr; 68(1):215-222.	
	AG	HIRASHIMA Y et al, "Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers". & ACTA Neurochir. (1995) 137(1-2):15- 18. (Dialog Information Services, File 154, MEDLINE, Dialog accession no. 08672149, Medline accession no. 96350619)	
	АН	KARASAWA et al, "Radioimmunoassay for platelet activating factor". Lipids. (1991). 26(12):1126-1129.	
	AI	LEMNE et al, "Carotid Intima-Media Thickness and Plaque Borderline Hypertension" STROKE, 26(1); pp. 34-39; 1995	
LK	A.J	OSTERMANN et al, "The degradation of platelet activating factor in serum and its discriminative value in atherosclerotic patients." Thrombosis Research. (1998). 52:529-540.	-
			-

Examiner Signature	Ofisar & Cook	Date Considered /2/7/05	
			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 1

Sheet

Co	omplete if Known	
Application Number	10/814,194	
Filing Date	April 1, 2004	
First Named Inventor	Johan FROSTEGARD	
Group Art Unit	1643 1641	
Examiner Name	L. Cook	
Attorney Docket Number	FROSTEGARD =1C	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AK	US-4,444,879	04-28-1984	FOSTER et al	
		us-			
		US-	, , , , , , , , , , , , , , , , , , , ,		
		us-			

		FOREIC	N PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	of Cited Desument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	_		-			
			·			
			-			

Examiner Date 12/2/05				
Signature Considered Considered	Examiner Signature	(Sug. Viork	Considered	12/7/05

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WiPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.' Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of | 1

Complete if Known				
Application Number	10/814,194			
Filing Date	April 1, 2004			
First Named Inventor	Johan FROSTEGARD			
Group Art Unit	1643 1641			
Examiner Name	L.Cook			
Attorney Docket Number	FROSTEGARD =1C			

xaminer iitials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
LYC	AL	A. ALBERTINI, et al; "Cost/Benefit and Predictive Value of Radioimmunoassay"; Symposia of the Giovanni Lorenzini Foundation; Vol. 18, pages 23-27.	
		·	
•			
			_

ı	Signature	Gesa person	Considered 7/ +100	
•				_

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.